DOC-20241228-WA0005.

Patient Name : Mr.
KRISHNA MOHAN THOTA Collected : 02/Oct/2024 09:16AM

Age/Gender : 51 Y 3 M 13 D /M Received : 02/Oct/2024 04:58PM
UHID/MR No : APJ1.0020883739 Reported : 02/Oct/2024 05:51PM
Visit ID : DMRZOPV2950 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PUP 24X7_CREDIT
IP/OP NO : Center location : Chandanagar,Hyderabad
DEPARTMENT OF HAEMATOLOGY
APOLLO BASIC FULL BODY CHECK
Test Name Result Unit Bio. Ref. Interval Method

HAEMOGLOBIN , WHOLE BLOOD EDTA 13.8 g/dL 13-17 Spectrophotometer
Page 1 of 7
SIN No:HA07771607
This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory,Hyderabad
Patient Name : Mr.KRISHNA MOHAN THOTA Collected : 02/Oct/2024 09:16AM
DEPARTMENT OF BIOCHEMISTRY
GLUCOSE FASTING & PP

GLUCOSE, FASTING , NAF PLASMA 87 mg/dL 70-100 Hexokinase
Comment:
As per American Diabetes Guidelines, 2023
Fasting Glucose Values in mg/dL Interpretation
70-100 mg/dL Normal
100-125 mg/dL Prediabetes
≥126 mg/dL Diabetes
<70 mg/dL Hypoglycemia
Note:
1.The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of
> or = 200 mg/dL on at least 2 occasions.
2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2 189 mg/dL 70-140 HEXOKINASE
HOURS , SODIUM FLUORIDE PLASMA
(2 HR)
Comment:
It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each
other.
Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive
hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin
preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.
Page 2 of 7
SIN No:BI22049094

GLUCOSE, RANDOM , SODIUM 92 mg/dL 70-140 HEXOKINASE
FLUORIDE PLASMA (R)
Page 3 of 7
SIN No:BI22049096

HBA1C (GLYCATED HEMOGLOBIN) , WHOLE BLOOD EDTA
HBA1C, GLYCATED HEMOGLOBIN 6.5 % HPLC
ESTIMATED AVERAGE GLUCOSE 140 mg/dL Calculated
(eAG)
Comment:
Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:
REFERENCE GROUP HBA1C %
NON DIABETIC <5.7
PREDIABETES 5.7 – 6.4
DIABETES ≥ 6.5
DIABETICS
EXCELLENT CONTROL 6–7
FAIR TO GOOD CONTROL 7–8
UNSATISFACTORY CONTROL 8 – 10
POOR CONTROL >10
Note: Dietary preparation or fasting is not required.
1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic
Control by American Diabetes Association guidelines 2023.
2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised
in interpretation of low Values.
4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not
accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
A: HbF >25%
B: Homozygous Hemoglobinopathy.
(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)
Page 4 of 7
SIN No:BI22049097
Page 5 of 7
SIN No:BI22049097
Page 6 of 7
SIN No:BI22049097

BILIRUBIN, TOTAL , SERUM 0.75 mg/dL 0.3–1.2 DPD

CREATININE , SERUM 0.72 mg/dL 0.84 - 1.25 Modified Jaffe, Kinetic
*** End Of Report ***
Page 7 of 7
SIN No:BI22049095
TERMS AND CONDITIONS GOVERNING THIS REPORT
The reported results are for information and interpretation of the referring doctor or such other medical professionals, who understand
reporting units, reference ranges and limitations of technologies.
Laboratories not be responsible for any interpretation whatsoever.
It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the verifications of the
particulars have been cleared out by the patient or his / her representative at the point of generation of said specimen.
The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same
parameter for the same patient.
Assays are performed in accordance with standard procedures, The reported results are dependent on individual assay methods /
equipment used and quality of specimen received.
This report is not valid for medico legal purposes.
SIN No:BI22049095

DOC-20241228-WA0005.

Uploaded by

Copyright:

Available Formats

DOC-20241228-WA0005.

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

DOC-20241228-WA0005.

Uploaded by

Copyright:

Available Formats

Patient Name : Mr.

KRISHNA MOHAN THOTA Collected : 02/Oct/2024 09:16AM

Test Name Result Unit Bio. Ref. Interval Method

Test Name Result Unit Bio. Ref. Interval Method

Test Name Result Unit Bio. Ref. Interval Method

Test Name Result Unit Bio. Ref. Interval Method

Test Name Result Unit Bio. Ref. Interval Method

Test Name Result Unit Bio. Ref. Interval Method

Test Name Result Unit Bio. Ref. Interval Method

* End Of Report *

TERMS AND CONDITIONS GOVERNING THIS REPORT

You might also like